News
Boehringer and Click's CT-155 plus antipsychotics significantly reduced negative symptoms associated with schizophrenia in a Phase III trial ...
Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback